NASDAQ:PRTA - Prothena Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.62 -0.24 (-1.62 %)
(As of 05/28/2018 03:40 AM ET)
Previous Close$14.86
Today's Range$14.48 - $15.15
52-Week Range$10.43 - $70.00
Volume403,893 shs
Average Volume963,043 shs
Market Capitalization$582.20 million
P/E Ratio-3.59
Dividend YieldN/A
Beta2.77

About Prothena (NASDAQ:PRTA)

Prothena logoProthena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta for the treatment of Alzheimer's disease; ALECT2 for ALECT2 amyloidosis; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and Sortilin for frontotemporal dementia and neuro inflammation. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop new therapies for a range of neurodegenerative diseases. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRTA
CUSIPN/A
Phone011-353-1236-2500

Debt

Debt-to-Equity RatioN/A
Current Ratio15.11
Quick Ratio15.11

Price-To-Earnings

Trailing P/E Ratio-3.59
Forward P/E Ratio-3.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.52 million
Price / Sales21.15
Cash FlowN/A
Price / CashN/A
Book Value$10.28 per share
Price / Book1.42

Profitability

EPS (Most Recent Fiscal Year)($4.07)
Net Income$-153,230,000.00
Net Margins-606.09%
Return on Equity-38.08%
Return on Assets-30.02%

Miscellaneous

Employees125
Outstanding Shares39,820,000

Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Corp (NASDAQ:PRTA) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by $0.03. The biotechnology company had revenue of $0.23 million for the quarter, compared to analyst estimates of $31.45 million. Prothena had a negative return on equity of 38.08% and a negative net margin of 606.09%. View Prothena's Earnings History.

When is Prothena's next earnings date?

Prothena is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Prothena.

What price target have analysts set for PRTA?

11 equities research analysts have issued 12 month target prices for Prothena's stock. Their forecasts range from $12.00 to $100.00. On average, they expect Prothena's stock price to reach $51.4545 in the next twelve months. View Analyst Ratings for Prothena.

What are Wall Street analysts saying about Prothena stock?

Here are some recent quotes from research analysts about Prothena stock:
  • 1. According to Zacks Investment Research, "The wider-than-expected loss in the first quarter was disappointing. The discontinuation of development of NEOD001 is a big setback for the company as it was the lead candidate. Nevertheless, Prothena’s license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive as it not only boosts pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. The company recently entered into an agreement with Celgene as well.  However,  Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates. Moreover, due to disappointing data from a phase Ib study, the company will not advance PRX003 into mid-stage development. Shares have performed worse than the industry in the last six months." (5/22/2018)
  • 2. Cantor Fitzgerald analysts commented, "Friday’s announcement that the CMO will resign her position may have created some disconcerting optics, but lacking any definitive details, we caution against over-interpreting the disclosure." (2/4/2018)

Who are some of Prothena's key competitors?

Who are Prothena's key executives?

Prothena's management team includes the folowing people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 49)
  • Mr. Tran B. Nguyen, Chief Financial Officer (Age 44)
  • Mr. Arthur W. Homan, Chief Legal Officer (Age 59)
  • Ms. Carol D. Karp, Chief Regulatory Officer (Age 65)
  • Dr. Martin Koller, Consultant (Age 67)

Has Prothena been receiving favorable news coverage?

News headlines about PRTA stock have been trending positive on Monday, according to Accern. The research group scores the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Prothena earned a daily sentiment score of 0.46 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.14 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Prothena's major shareholders?

Prothena's stock is owned by a number of of institutional and retail investors. Top institutional investors include Woodford Investment Management Ltd (29.97%), BlackRock Inc. (7.48%), Palo Alto Investors LP (2.77%), BB Biotech AG (1.04%), Pinnacle Associates Ltd. (0.83%) and Westfield Capital Management Co. LP (0.80%). Company insiders that own Prothena stock include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena.

Which institutional investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, BlackRock Inc., Eventide Asset Management LLC, Oak Ridge Investments LLC, Pinnacle Associates Ltd., JPMorgan Chase & Co., Schwab Charles Investment Management Inc. and DekaBank Deutsche Girozentrale. Company insiders that have sold Prothena company stock in the last year include Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker and Tara Nickerson. View Insider Buying and Selling for Prothena.

Which institutional investors are buying Prothena stock?

PRTA stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Thrivent Financial for Lutherans, BB Biotech AG, A.R.T. Advisors LLC, Woodford Investment Management Ltd, Trexquant Investment LP, Credit Agricole S A and Employees Retirement System of Texas. View Insider Buying and Selling for Prothena.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $14.62.

How big of a company is Prothena?

Prothena has a market capitalization of $582.20 million and generates $27.52 million in revenue each year. The biotechnology company earns $-153,230,000.00 in net income (profit) each year or ($4.07) on an earnings per share basis. Prothena employs 125 workers across the globe.

How can I contact Prothena?

Prothena's mailing address is UPPER GEORGE`S STREET, DUN LAOGHAIRE CO. DUBLIN L2, A96 T927. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]


MarketBeat Community Rating for Prothena (PRTA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  348 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  555
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Prothena (NASDAQ:PRTA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Prothena in the last 12 months. Their average twelve-month price target is $51.4545, suggesting that the stock has a possible upside of 251.95%. The high price target for PRTA is $100.00 and the low price target for PRTA is $12.00. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.362.502.922.92
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.4545$54.9091$76.4545$77.7273
Price Target Upside: 251.95% upside377.47% upside147.03% upside49.68% upside

Prothena (NASDAQ:PRTA) Consensus Price Target History

Price Target History for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2018OppenheimerReiterated RatingHoldLowView Rating Details
5/21/2018BarclaysDowngradeEqual Weight ➝ Underweight$12.00HighView Rating Details
4/24/2018NomuraLower Price TargetBuy ➝ Buy$87.00 ➝ $19.00HighView Rating Details
4/24/2018WedbushLower Price TargetNeutral$46.00 ➝ $13.00HighView Rating Details
4/24/2018BTIG ResearchDowngradeBuy ➝ Neutral$77.00HighView Rating Details
4/24/2018Deutsche BankReiterated RatingBuy ➝ Buy$78.00 ➝ $16.00HighView Rating Details
4/24/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$69.00 ➝ $14.00HighView Rating Details
4/23/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$87.00HighView Rating Details
4/23/2018Jefferies GroupDowngradeBuy ➝ HoldHighView Rating Details
10/2/2017SunTrust BanksReiterated RatingBuy$75.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$83.00HighView Rating Details
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy ➝ Buy$87.00N/AView Rating Details
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/AView Rating Details
8/4/2016UBSReiterated RatingBuy$73.00N/AView Rating Details
(Data available from 5/28/2016 forward)

Earnings

Prothena (NASDAQ:PRTA) Earnings History and Estimates Chart

Earnings by Quarter for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA) Earnings Estimates

2018 EPS Consensus Estimate: ($4.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.49)($0.83)($1.20)
Q2 20183($1.29)($0.82)($1.05)
Q3 20183($1.38)($0.63)($0.91)
Q4 20183($1.49)($0.51)($0.88)

Prothena (NASDAQ PRTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($1.23)N/AView Earnings Details
5/8/20183/31/2018($1.23)($1.26)$31.45 million$0.23 millionViewN/AView Earnings Details
2/14/2018After Market($1.48)($1.24)$0.27 million$0.23 millionViewListenView Earnings Details
11/7/2017Q3($1.41)($1.37)$0.28 million$0.19 millionViewN/AView Earnings Details
8/8/20176/30/2017($0.89)($0.46)$16.08 million$26.81 millionViewN/AView Earnings Details
5/9/20173/31/2017($1.32)($0.99)$0.26 million$0.26 millionViewN/AView Earnings Details
2/14/2017Q416($1.12)($1.41)$5.35 million$0.20 millionViewListenView Earnings Details
11/1/2016Q3($1.22)($1.26)$0.49 million$0.29 millionViewN/AView Earnings Details
8/2/2016Q2($0.91)($1.18)$0.39 million$0.33 millionViewN/AView Earnings Details
5/3/2016Q116($0.77)($0.81)$0.27 million$0.27 millionViewN/AView Earnings Details
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details
11/2/2015($0.66)($0.73)$0.28 million$0.43 millionViewN/AView Earnings Details
8/4/2015Q2($0.56)($0.59)$0.60 million$0.28 millionViewN/AView Earnings Details
5/5/2015($0.59)($0.55)$1.95 million$0.59 millionViewN/AView Earnings Details
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details
8/4/2014Q214$0.06$15.17 million$15.12 millionViewN/AView Earnings Details
5/5/2014$0.81$0.78$30.17 million$32.23 millionViewN/AView Earnings Details
3/6/2014Q113($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.62)($0.55)$0.14 million$0.17 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.53)($0.64)$0.14 million$0.17 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.51)$0.17 millionViewN/AView Earnings Details
3/28/2013Q412($0.82)$0.1270 million$0.5750 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Prothena (NASDAQ:PRTA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Prothena (NASDAQ PRTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.70%
Insider Trading History for Prothena (NASDAQ:PRTA)
Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ PRTA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2017Dennis J SelkoeDirectorSell3,500$64.17$224,595.00View SEC Filing  
9/28/2017Christopher S HenneyDirectorSell900$70.00$63,000.00900View SEC Filing  
9/28/2017Gene G KinneyInsiderSell2,800$70.00$196,000.005,593View SEC Filing  
9/27/2017Tara NickersonInsiderSell4,724$69.05$326,192.206,724View SEC Filing  
9/25/2017Tara NickersonInsiderSell17,500$63.60$1,113,000.0019,500View SEC Filing  
7/17/2017Karin L WalkerInsiderSell5,000$64.89$324,450.005,000View SEC Filing  
7/7/2017Dennis J SelkoeDirectorSell3,500$58.11$203,385.006,345View SEC Filing  
4/17/2017Karin L WalkerInsiderSell5,000$52.25$261,250.003,000View SEC Filing  
4/3/2017Dennis J SelkoeDirectorSell3,500$55.86$195,510.006,345View SEC Filing  
3/9/2017Tran NguyenCFOBuy1,000$51.32$51,320.003,200View SEC Filing  
1/4/2017Arthur W HomanInsiderSell3,125$52.25$163,281.25413View SEC Filing  
11/28/2016Dennis J SelkoeDirectorSell5,000$62.42$312,100.007,845View SEC Filing  
11/9/2016Gene G KinneyInsiderSell8,548$55.32$472,875.3611,341View SEC Filing  
10/21/2016Gene G KinneyInsiderSell20,619$55.10$1,136,106.9017,578View SEC Filing  
10/13/2016Karin L WalkerInsiderSell5,000$54.23$271,150.003,000View SEC Filing  
9/19/2016Karin L WalkerInsiderSell12,000$61.10$733,200.007,000View SEC Filing  
9/1/2016Arthur W HomanInsiderSell3,125$52.16$163,000.003,125View SEC Filing  
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.509,375View SEC Filing  
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.003,025View SEC Filing  
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.002,000View SEC Filing  
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.007,845View SEC Filing  
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.002,000View SEC Filing  
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.002,200View SEC Filing  
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.502,845View SEC Filing  
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00243View SEC Filing  
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.002,000View SEC Filing  
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.252,845View SEC Filing  
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.003,333View SEC Filing  
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.008,161View SEC Filing  
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.002,000View SEC Filing  
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.002,793View SEC Filing  
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.002,200View SEC Filing  
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Prothena (NASDAQ PRTA) News Headlines

Source:
DateHeadline
PRTA INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Prothena Corporation ...PRTA INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Prothena Corporation ...
www.businesswire.com - May 26 at 9:42 AM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Prothena Corporation (PRTA)The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Prothena Corporation (PRTA)
www.businesswire.com - May 25 at 4:08 PM
 The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Prothena Corporation (PRTA) The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Prothena Corporation (PRTA)
finance.yahoo.com - May 25 at 4:08 PM
Prothena Corp (PRTA) Receives Average Rating of "Hold" from BrokeragesProthena Corp (PRTA) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 25 at 3:41 PM
Prothena (PRTA) Receives Hold Rating from OppenheimerProthena (PRTA) Receives Hold Rating from Oppenheimer
www.americanbankingnews.com - May 25 at 3:01 PM
PRTA INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Prothena Corporation InvestorsPRTA INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Prothena Corporation Investors
finance.yahoo.com - May 25 at 9:42 AM
Prothena Corp. (PRTA) Announces Reorganization, Reports Discontinuation of NEOD001 Development ProgramProthena Corp. (PRTA) Announces Reorganization, Reports Discontinuation of NEOD001 Development Program
www.streetinsider.com - May 24 at 4:11 PM
PRTA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena CorporationPRTA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena Corporation
finance.yahoo.com - May 24 at 4:11 PM
Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience PipelineProthena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline
finance.yahoo.com - May 24 at 10:05 AM
PROTHENA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The FirmPROTHENA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The Firm
finance.yahoo.com - May 24 at 10:05 AM
Prothena to lay off more than half its staff as part of reorganizationProthena to lay off more than half its staff as part of reorganization
finance.yahoo.com - May 24 at 10:05 AM
PRTA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving ...PRTA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving ...
www.businesswire.com - May 22 at 4:09 PM
PRTA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena CorporationPRTA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena Corporation
finance.yahoo.com - May 22 at 4:09 PM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Prothena Corporation plc (Nasdaq: PRTA) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Prothena Corporation plc (Nasdaq: PRTA) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - May 22 at 9:44 AM
Prothena (PRTA) Downgraded by Barclays to SellProthena (PRTA) Downgraded by Barclays to Sell
www.americanbankingnews.com - May 21 at 11:03 AM
Barclays Downgrades Prothena Corp (PRTA) to UnderweightBarclays Downgrades Prothena Corp (PRTA) to Underweight
www.streetinsider.com - May 21 at 9:52 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena CorporationINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena Corporation
finance.yahoo.com - May 19 at 9:48 AM
Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Prothena ...Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Prothena ...
www.prnewswire.com - May 18 at 11:11 AM
Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Prothena Corporation plc And Certain Of Its Current And Former Senior ExecutivesBernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Prothena Corporation plc And Certain Of Its Current And Former Senior Executives
finance.yahoo.com - May 18 at 11:11 AM
Prothena Corp (PRTA) Expected to Announce Quarterly Sales of $270,000.00Prothena Corp (PRTA) Expected to Announce Quarterly Sales of $270,000.00
www.americanbankingnews.com - May 18 at 5:01 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Encourages Investors Who Suffered Losses Exceeding ...SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Encourages Investors Who Suffered Losses Exceeding ...
www.prnewswire.com - May 17 at 4:03 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Encourages Investors Who Suffered Losses Exceeding $2,000,000 Investing In Prothena Corporation plc (PRTA) To Contact The FirmSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Encourages Investors Who Suffered Losses Exceeding $2,000,000 Investing In Prothena Corporation plc (PRTA) To Contact The Firm
finance.yahoo.com - May 17 at 4:03 PM
PROTHENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 ...PROTHENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 ...
www.prnewswire.com - May 17 at 10:01 AM
PROTHENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Prothena Corporation plc To Contact The FirmPROTHENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Prothena Corporation plc To Contact The Firm
finance.yahoo.com - May 17 at 10:01 AM
Prothena (PRTA) Upgraded to "Buy" at Zacks Investment ResearchProthena (PRTA) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 16 at 1:35 PM
-$1.11 EPS Expected for Prothena Corp (PRTA) This Quarter-$1.11 EPS Expected for Prothena Corp (PRTA) This Quarter
www.americanbankingnews.com - May 16 at 5:22 AM
Q2 2018 EPS Estimates for Prothena Corp (PRTA) Increased by AnalystQ2 2018 EPS Estimates for Prothena Corp (PRTA) Increased by Analyst
www.americanbankingnews.com - May 14 at 1:56 AM
Q2 2018 EPS Estimates for Prothena Corp Boosted by Oppenheimer (PRTA)Q2 2018 EPS Estimates for Prothena Corp Boosted by Oppenheimer (PRTA)
www.americanbankingnews.com - May 14 at 1:56 AM
Q2 2018 EPS Estimates for Prothena Corp (PRTA) Reduced by WedbushQ2 2018 EPS Estimates for Prothena Corp (PRTA) Reduced by Wedbush
www.americanbankingnews.com - May 14 at 1:56 AM
FY2022 EPS Estimates for Prothena Corp (PRTA) Lifted by AnalystFY2022 EPS Estimates for Prothena Corp (PRTA) Lifted by Analyst
www.americanbankingnews.com - May 11 at 11:52 AM
Prothena Corp Expected to Post Q2 2018 Earnings of ($1.27) Per Share (PRTA)Prothena Corp Expected to Post Q2 2018 Earnings of ($1.27) Per Share (PRTA)
www.americanbankingnews.com - May 11 at 9:39 AM
Form 10-Q Prothena Corp plc For: Mar 31Form 10-Q Prothena Corp plc For: Mar 31
www.streetinsider.com - May 10 at 10:06 AM
Prothenas (PRTA) "Hold" Rating Reiterated at OppenheimerProthena's (PRTA) "Hold" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - May 10 at 9:08 AM
Prothena (PRTA) Issues  Earnings Results, Misses Expectations By $0.03 EPSProthena (PRTA) Issues Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 9 at 6:35 PM
BRIEF-Prothena Reports Q1 Loss Per Share $1.26BRIEF-Prothena Reports Q1 Loss Per Share $1.26
www.reuters.com - May 9 at 9:54 AM
Prothena: 1Q Earnings SnapshotProthena: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:54 AM
Prothena Reports First Quarter 2018 Financial Results and Provides R&D UpdateProthena Reports First Quarter 2018 Financial Results and Provides R&D Update
finance.yahoo.com - May 9 at 9:54 AM
Prothena (PRTA) Q1 Loss Wider Than Expected, Sales MissProthena (PRTA) Q1 Loss Wider Than Expected, Sales Miss
finance.yahoo.com - May 9 at 9:54 AM
Woodford Patient Trust Has Poor April On Prothena News - QuotedDataWoodford Patient Trust Has Poor April On Prothena News - QuotedData
www.lse.co.uk - May 4 at 9:45 AM
Whats in Store for Prothena (PRTA) This Earnings Season?What's in Store for Prothena (PRTA) This Earnings Season?
www.zacks.com - May 4 at 9:45 AM
Prothena Corp Expected to Post FY2018 Earnings of ($3.52) Per Share (PRTA)Prothena Corp Expected to Post FY2018 Earnings of ($3.52) Per Share (PRTA)
www.americanbankingnews.com - May 2 at 9:30 AM
Prothena Corp (PRTA) Receives Average Rating of "Hold" from AnalystsProthena Corp (PRTA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 30 at 5:34 PM
Prothena (PRTA) Set to Announce Quarterly Earnings on MondayProthena (PRTA) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 4:28 AM
Zacks: Analysts Expect Prothena Corp (PRTA) Will Post Quarterly Sales of $31.45 MillionZacks: Analysts Expect Prothena Corp (PRTA) Will Post Quarterly Sales of $31.45 Million
www.americanbankingnews.com - April 30 at 2:42 AM
Biotech investment fraught with pitfalls as Woodford discoversBiotech investment fraught with pitfalls as Woodford discovers
www.ft.com - April 29 at 3:59 PM
Prothena Corp (PRTA) Expected to Announce Earnings of -$1.23 Per ShareProthena Corp (PRTA) Expected to Announce Earnings of -$1.23 Per Share
www.americanbankingnews.com - April 28 at 5:04 PM
Prothena (PRTA) Stock Rating Lowered by Zacks Investment ResearchProthena (PRTA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 26 at 12:56 PM
Wedbush Weighs in on Prothena Corps FY2019 Earnings (PRTA)Wedbush Weighs in on Prothena Corp's FY2019 Earnings (PRTA)
www.americanbankingnews.com - April 26 at 11:05 AM
Prothena Corp to Post Q1 2018 Earnings of ($1.29) Per Share, Jefferies Group Forecasts (PRTA)Prothena Corp to Post Q1 2018 Earnings of ($1.29) Per Share, Jefferies Group Forecasts (PRTA)
www.americanbankingnews.com - April 26 at 8:12 AM
Prothena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout TargetProthena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout Target
seekingalpha.com - April 25 at 4:03 PM

SEC Filings

Prothena (NASDAQ:PRTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Prothena (NASDAQ:PRTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Prothena (NASDAQ PRTA) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.